| NCT ID | NCT06011694 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing Shihejiyin Technology, Inc. |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2022-06-15 |
| Primary Completion | 2027-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2022-06-15 with a primary completion date of 2027-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.
Eligibility Criteria
Inclusion Criteria: 1、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent Exclusion Criteria: 1. Pregnant women; 2. Individuals who have history of cancer or current diagnosis of cancer; 3. Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant; 4. Individulas who have blood transfusion within 30 days prior to the blood draw; 5. Individuals who have an acute infection or inflammation within 14 days prior to the blood draw; 6. Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw; 7. Individuals who will not be able to comply with the protocol procedures judged by researchers
Contact & Investigator
Shao Yang, Ph.D
PRINCIPAL INVESTIGATOR
NanjingShihejiyin Technology Inc.
Frequently Asked Questions
Who can join the NCT06011694 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 75 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06011694 currently recruiting?
Yes, NCT06011694 is actively recruiting participants. Contact the research team at admin@geneseeq.com for enrollment information.
Where is the NCT06011694 trial being conducted?
This trial is being conducted at Nanjing, China, Nanjing, China.
Who is sponsoring the NCT06011694 clinical trial?
NCT06011694 is sponsored by Nanjing Shihejiyin Technology, Inc.. The principal investigator is Shao Yang, Ph.D at NanjingShihejiyin Technology Inc.. The trial plans to enroll 15,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.